USFDA issues Complete Response Letter to Dr. Reddy’s for AVT03 (denosumab) citing Alvotech facility observations

What the CRL means and next steps

 

The USFDA’s CRL indicates that AVT03’s Biologics License Application is not approvable in its current form, primarily due to pre‑license inspection findings at Alvotech’s facility that manufactures the product. AVT03 targets denosumab indications (osteoporosis and oncology supportive care) as a biosimilar to Prolia and Xgeva. Dr. Reddy’s and Alvotech will need to implement corrective actions, submit documentation, and likely undergo re‑inspection before resubmission. Investors should watch for details on remediation scope, projected timelines, and whether any additional clinical or analytical data will be requested, which can affect commercialization schedules and market entry dynamics. 

 

Important points / notable updates

 

Sources: CNBC-TV18; company communication summarized in market reports; InvestyWise/ScanX summaries referencing USFDA CRL.